Astellas announces 'golden ticket' winners

By The Science Advisory Board staff writers

October 8, 2020 -- Astellas Venture Management, a subsidiary of Astellas Pharma and LabCentral, announced that Axonis Therapeutics and Tenza are the 2020 winners of the "Golden Ticket Competition."

The award offers scientists or biotechnology startups one-year usage of LabCentral's lab facility in Cambridge, MA, as well as access to Astellas' research and development capabilities and business leaders.

Axonis is advancing research for spinal cord injury and other neurological disorders. The company is conducting preclinical studies of its novel small-molecule technology.

Tenza is developing orally available therapeutics for mucosal disease by engineering probiotic microbes to produce and deliver drugs directly to gut tissue.

Both Axonis and Tenza will continue their residence at LabCentral with the next year sponsored by Astellas. Both will be supported by the Astellas team and the Astellas Biomedical Innovation Hub organizations in the Boston area to maximize their progress.

Astellas, MBC BioLabs call for scientists to enter 'Golden Ticket Competition'
Astellas Venture Management and Mission Bay Capital BioLabs (MBC BioLabs) are collaborating again on the "Golden Ticket Competition," which offers up...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter